UBE3A
Chr 15ADubiquitin protein ligase E3A
Also known as: ANCR, AS, E6-AP, EPVE6AP, HPVE6A, PIX1
This gene encodes an E3 ubiquitin-protein ligase, part of the ubiquitin protein degradation system. This imprinted gene is maternally expressed in brain and biallelically expressed in other tissues. Maternally inherited deletion of this gene causes Angelman Syndrome, characterized by severe motor and intellectual retardation, ataxia, hypotonia, epilepsy, absence of speech, and characteristic facies. The protein also interacts with the E6 protein of human papillomavirus types 16 and 18, resulting in ubiquitination and proteolysis of tumor protein p53. Alternative splicing of this gene results in three transcript variants encoding three isoforms with different N-termini. Additional transcript variants have been described, but their full length nature has not been determined. [provided by RefSeq, Jul 2008]
Primary Disease Associations & Inheritance
Clinical highlights
- GTX-102ASOPhase 1/2
Suppresses UBE3A-AS to reactivate the silenced paternal UBE3A.
Delivery: Intrathecal - ION582ASOPhase 1/2
Reactivates paternal UBE3A (same de-repression mechanism).
Delivery: Intrathecal
Therapeutic landscape as of 2026-07. Educational only. Investigational ≠ available; not medical advice or eligibility. Approved entries are precise; investigational program names/phases are conservative and move fast. Curated from FDA/EMA approvals and the clinical-trial literature; verify against current labeling + ClinicalTrials.gov.
ClinicalTrials.govPopulation Genetics & Constraint
gnomAD v4 — loss-of-function & missense intolerance
Highly LoF-intolerant (top ~10% of genes)
Highly missense-constrained (top ~0.1%)
ClinVar Variant Classifications
0 submitted variants in ClinVar
Protein Context — Lollipop Plot
UBE3A · protein map & ClinVar variants
Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.
External Resources
Links to major genomics databases and tools
Clinical Trials
Active and recruiting trials from ClinicalTrials.gov
Investigating the Therapeutic Efficacy of All-trans Retinoic Acid in Autism Spectrum Disorder Patients With 15q11-13 Duplication Syndrome
NOT YET RECRUITINGA Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome
RECRUITINGREVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome
RECRUITINGExternal Resources
Links to major genomics databases and tools